SLC12A5 and cancer: The study aimed to determine the differences in the primary cell response of IDH-wildtype GBMs to treatment with the sodium valproate and sodium dichloroacetate combination (NaVPA–NaDCA) by assessing the expression of cancer marker genes SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP, and to compare these effects with those of TMZ.